Haisco Pharmaceutical Group Co (SZSE:002653) LT-Debt-to-Total-Asset : 0.14 (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Haisco Pharmaceutical Group Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Haisco Pharmaceutical Group Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.14.

Haisco Pharmaceutical Group Co's long-term debt to total assets ratio declined from Mar. 2023 (0.15) to Mar. 2024 (0.14). It may suggest that Haisco Pharmaceutical Group Co is progressively becoming less dependent on debt to grow their business.

Haisco Pharmaceutical Group Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Haisco Pharmaceutical Group Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haisco Pharmaceutical Group Co LT-Debt-to-Total-Asset Chart

Haisco Pharmaceutical Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.07

0.09

0.22

0.13

Haisco Pharmaceutical Group Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.15	0.13	0.12	0.13	0.14

Haisco Pharmaceutical Group Co LT-Debt-to-Total-Asset Calculation

Haisco Pharmaceutical Group Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	865.529	/	6652.886
	=	0.13

Haisco Pharmaceutical Group Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	948.001	/	6842.783
	=	0.14

Haisco Pharmaceutical Group Co (SZSE:002653) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Haisco Pharmaceutical Group Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Haisco Pharmaceutical Group Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Haisco Pharmaceutical Group Co (SZSE:002653) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Haisco Pharmaceutical Group Co Ltd (SZSE:002653) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 17, Sanxiang Avenue, Shannan District, Tibet Autonomous Region, Zetang, CHN, 856000

Website

http://www.haisco.com

Haisco Pharmaceutical Group Co Ltd is a pharmaceutical company based in China. It is mainly engaged in the research, development, manufacture, and sale of drugs for liver disease. Its product portfolio includes parenteral nutrition drugs, antibiotics, anesthetic agents, digestive system drugs and tumour adjuvant drug series. The company's products are being used in first rank hospitals in China.

Executives

Fan Xiu Lian	Directors, executives
Zheng Wei	Directors, executives
Wang Meng	Secretary Dong
Wang Jun Min	Directors, executives
Deng Xiang	Directors, executives
Liu Han Bing	Supervisors
Zhang Xiao Xu	Supervisors
Tan Hong	Executives
Shen Ping	Director
Liang Yong	Supervisors
Chen Long	Independent director
Duan Qing Liang	Supervisors

Haisco Pharmaceutical Group Co (SZSE:002653) Headlines

No Headlines